hrp0095p1-153 | Pituitary, Neuroendocrinology and Puberty | ESPE2022

Urinary gonadotrophins as markers of puberty in girls and boys during late childhood and adolescence: Evidence from the SCAMP Cohort

Spiers Alexander , Patjamontri Supitcha , B Smith Rachel , Shen Chen , B. Toledano Mireille , Faisal Ahmed S

Introduction: Urinary gonadotrophins measurement is a noninvasive method for evaluation of pubertal development and may have utility in population studies.Objectives: To investigate the utility of urinary gonadotrophins as a noninvasive biomarker of puberty in boys and girls.Methods: School-based adolescent cohort study with two time points for collecting school time urine samples ...

hrp0095p1-26 | Bone, Growth Plate and Mineral Metabolism | ESPE2022

Outcomes of four patients with osteonecrosis after one-year pamidronate treatment

Yüksek Acinikli Kübra , Besci Özge , Yaşar Elif , Tüfekçi Özlem , Karadağ Zehra , Yıldız Gizem , Torun Rüya , Akın Kağızmanlı Gözde , Torun Bayram Meral , Yılmaz Şebnem , Güleryüz Handan , Abacı Ayhan , Böber Ece , Demir Korcan

Background: Osteonecrosis (ON) is bone death caused by inadequate blood supply resulting in demineralization and trabecular thinning and, subsequently, mechanical failure. Although the pathophysiology of ON is not fully understood, the use of high-dose glucocorticoid (GC) is one of the triggers. Furthermore, its optimal management remains uncertain. The use of bisphosphonates (BP) for the treatment of ON has been reported, however, data on outcomes are limited...

hrp0084p2-580 | Thyroid | ESPE2015

The Diagnostic, Treatment and Follow-Up Features of Childhood Thyroid Malignancies – A Preliminary Report

Bideci Aysun , Yesilkaya Ediz , Berberoglu Merih , Siklar Zeynep , Darcan Sukran , Ozen Samim , Bas Serpil , Doger Esra , Eren Erdal , Turan Serap , Akinci Aysehan , Demirel Fatma , Simsek Enver , Cetinkaya Semra , Bircan Iffet , Aydin Murat , Bober Ece , Sari Erkan , Hatipoglu Nihal , Tayfun Meltem , Saglam Halil , Ozbek Mehmet Nuri , Yildirim Ruken , Dundar Bumin , Cayir Atilla , Alagoz Engin , Atas Erman

Background: Thyroid cancer is a very rare malignancy of childhood. Approximately they account for 1.5% of all cancers before 15 years of age. In our country, this rate is %0.4 before 20 years of age.Aims and objectives: To analyses the clinical features and treatment results of children with thyroid malignancy in Turkey.Methods: In this multicentric and retrospective study the demographic and clinical characteristics of 124 childre...

hrp0084p3-981 | GH & IGF | ESPE2015

Current Practice in Diagnosis and Treatment of GH Deficiency in Childhood: A Survey from Turkey

Poyrazoglu Sukran , Akcay Teoman , Atabek Mehmet Emre , Bideci Aysun , Bircan Iffet , Bober Ece , Can Sule , Darcan Sukran , Ersoy Betul , Guven Ayla , Kara Cengiz , Keskin Mehmet , Kurtoglu Selim , Ozbek Mehmet Nuri , Ozgen Tolga , Siklar Zeynep , Simsek Enver , Turan Serap , Yuksel Bilgin , Darendeliler Feyza

Background: Diagnosis and treatment of GH deficiency(GHD) in children are different between countries, and even among centres in the same country.Objective and hypotheses: To evaluate current practices in diagnosis and treatment of GHD in the process of preparing the new consensus on GHD by Turkish Society for Pediatric Endocrinology and Diabetes.Method: A questionnaire was sent out to all paediatric endocrinology centres.<p cl...

hrp0097rfc4.3 | Growth and syndromes (to include Turner syndrome) | ESPE2023

Aromatase inhibitors: an effective and safe option for height increment in boys with growth hormone deficiency?

Kağızmanlı Gözde Akın , Özalp Kızılay Deniz , Besci Özge , Yüksek Acinikli Kübra , Özen Samim , Demir Korcan , Damla Gökşen Şimşek Ruhsar , Böber Ece , Darcan Şükran , Abacı Ayhan

Background: Aromatase inhibitors (AIs) have been suggested to slow down estrogen-dependent skeletal maturation in pubertal boys with short stature. In the literature, few studies evaluate the efficacy and safety of AIs in boys with growth hormone deficiency (GHD). Objective: To evaluate the auxologic effects and short-term laboratory profiles of combined AI and rhGH therapy in adolescent males with GHD.Subjects and Methods:</stro...

hrp0095p2-148 | GH and IGFs | ESPE2022

Height Velocity in Indonesian Children Receiving Growth Hormone Therapy

B Pulungan Aman , A Andarie Attika , Lestari Pramesti Dwi

Background: Short stature is one of the most common conditions referred to pediatric endocrinology clinics, and treatment with growth hormone (GH) is useful to improve height velocity and adult height, but response may be variable. Growth hormone therapy is indicated in several conditions in pediatric patients, including growth hormone deficiency (GHD) and children born short for gestational age (SGA). We investigated differences in treatment response in Indon...

hrp0092p1-363 | GH and IGFs (2) | ESPE2019

Metabolism of Somapacitan, a Long-Acting Growth Hormone Derivative, in Human Subjects

Damholt Birgitte B , Bjelke Mads , Helleberg Hans , Rasmussen Michael H

Background: Somapacitan is a reversible albumin-binding growth hormone (GH) derivative developed for once-weekly administration in patients with GH deficiency (GHD). It consists of a human GH backbone, similar to endogenous human GH, with one amino acid substitution, attached to an albumin binder via a linker chain.Objective: Absorption, metabolism and excretion (AME) of somapacitan were investigated in a Phase 1 trial (...

hrp0089p2-p277 | Growth &amp; Syndromes P2 | ESPE2018

Pulling the Brakes – ‘Catch Down Growth’: A Phenomenon for Achieving Mid-parental Height Centile After Acquired, All-cause, Brain Injury

Kraus Fabian B T , Hindmarsh Peter C , Spoudeas Helen A

Introduction: Of any pituitary dysfunction following brain injury, growth hormone (GH) deficiency (GHD) is the most prevalent. The cut-point for defining GHD has been placed at 7 ng/mL representing optimum test performance. We hypothesised this cut-off may be set too low for genetically taller children with acquired brain injury, notably brain tumours, who demonstrate severe growth failure but repeatedly fail to meet diagnostic thresholds for GH replacement until several centi...

hrp0082p2-d3-387 | Fat Metabolism &amp; Obesity (2) | ESPE2014

Enhanced Liver Fibrosis Test in Obese Children with Ultrasound-Proven Steatosis

Sztefko Krystyna , Szybowska Patrycja , Wojcik Malgorzata , Starzyk Jerzy B

Background: Non-alcoholic fatty liver disease (NAFLD) in obese children is a diagnostic challenge. Presently recommended markers of liver steatosis and risk of progression to fibrosis are: ultrasound imaging (US) and liver aminotransferases (ALT and AST). Owing to the poor sensitivity of these tests, there is a need to search for biomarkers which could indicate early stages of NAFLD. The enhanced liver fibrosis test (ELF) based on the combination of serum concentration of hyal...

hrp0094p2-375 | Pituitary, neuroendocrinology and puberty | ESPE2021

Salivary sex steroids as markers of puberty in boys during late childhood and adolescence

Patjamontri Supitcha , Spiers Alexander , Smith Rachel B , Shen Chen , Adaway Jo , G Keevil Brian , Toledano Mireille B , Ahmed S Faisal ,

Introduction: Salivary androgens represent a non-invasive marker of puberty that may have utility in population studies as well as in the clinical arena.Objectives: To establish normal reference values of salivary androgens using LC-MS/MS and demonstrate the correlations between salivary androgens and pubertal development in boys.Methods: School-based adolescent cohort study with t...